<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; lawmakers</title>
	<atom:link href="http://www.tapanray.in/tag/lawmakers/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s Drug Pricing Policy: “Absurd, Unreasonable And Irrational&#8221; – Supreme Court</title>
		<link>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court</link>
		<comments>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/#comments</comments>
		<pubDate>Mon, 20 Jul 2015 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1996]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Achhe din]]></category>
		<category><![CDATA[All India Drug Action Network]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[coat-based drug pricing]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[irrational]]></category>
		<category><![CDATA[JSA]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[Market Based Drug-Pricing]]></category>
		<category><![CDATA[NGO]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Policy. Absurd]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Unreasonable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6830</guid>
		<description><![CDATA[On July 15, 2015, while hearing a petition related to the current &#8216;Market Based Drug-Pricing Policy&#8217; of the country, the Supreme Court of India expressed its bewilderment on the very rationality of the ‘National Pharmaceutical Pricing Policy 2012’ and directed the &#8230; <a href="http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-pricing-policy-absurd-unreasonable-and-irrational-supreme-court/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New “National IPR Policy” of India – A Pharma Perspective</title>
		<link>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-national-ipr-policy-of-india-a-pharma-perspective</link>
		<comments>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/#comments</comments>
		<pubDate>Mon, 19 Jan 2015 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Justice]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prabha]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Sridevan]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6330</guid>
		<description><![CDATA[Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high &#8230; <a href="http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
